Novel Software Systems

Novel Software Systems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NOVEL is a privately held, revenue-generating bioinformatics software and services company founded in 2004, with a strong operational footprint in Russia, the US, China, and the Netherlands. Its core business revolves around two main platforms: 'NGS Wizard' for automated NGS data processing and 'Protomenal' for functional protein analysis, both designed to be accessible to users without deep technical expertise. With a team of over 50 specialists, the company leverages its interdisciplinary expertise to solve complex problems at the intersection of biology, mathematics, and IT, positioning itself in the high-growth markets of AI, personalized medicine, and genomic services.

Digital HealthAI / Machine Learning

Technology Platform

Proprietary bioinformatics software platforms for automated NGS data processing (NGS Wizard) and functional protein analysis (Protomenal), integrated with big data processing, cloud computing, and machine learning/AI capabilities.

Opportunities

The company is positioned in high-growth markets driven by AI in life sciences, personalized medicine, and genomic data explosion.
Its user-friendly software platforms can capture demand from biotech and pharma companies seeking to democratize data analysis.
Global office network provides a foundation for international expansion.

Risk Factors

Significant geopolitical risk due to core operations in Russia, potentially affecting global collaboration, sales, and talent acquisition.
Faces intense competition in the bioinformatics software market from both large corporations and startups.
Execution risk in maintaining rapid AI/ML innovation and technological edge.

Competitive Landscape

NOVEL competes in the crowded bioinformatics software and services market against large players like Illumina (BaseSpace), QIAGEN (CLC Bio), Thermo Fisher, and pure-play software companies like DNAnexus and Partek, as well as numerous academic and open-source tools. Its differentiation lies in emphasizing ease-of-use for non-experts and a combined focus on genomics and proteomics.